José L. Lanciego

José L. Lanciego is a Staff Scientist at the Center for Applied Medical Research (CIMA), and Associate Professor of Neurosciences at the University of Navarra Medical School, Pamplona, Spain. Originally trained as a Medical Doctor (University of Salamanca, June 1990), he received his PhD in Neurosciences with honors at the University of Salamanca in October 1994. Later on he joined the Department of Anatomy at the Amsterdam Vrije Universiteit, as a postdoctoral fellow under the supervision of Dr. Floris G. Wouterlood (1992 and 1996), with a main focus on neuroanatomical tract-tracing techniques. In February 1997 he moved to the University of Navarra to be engaged in studies dealing with the neurobiology of Parkinson’s disease. At present, he is ahead of the Laboratory of Functional Basal Ganglia Neuroanatomy at CIMA. His recent research interests include a number of projects dealing with the pathophysiology of Parkinson’s disease using non-human primate models. Ongoing work focuses on gene therapy approaches for Parkinson’s disease. He is co-editor of the third edition of Neuroanatomical Tract-Tracing Methods, Associate Editor of Frontiers in Neuroanatomy and Frontiers in Molecular Neuroscience as well as a member of the Editorial Board of Brain Structure and Function, International Journal of Medical Sciences and Frontiers in Neuropharmacology. He is a member of the Society for Neuroscience (SfN; US), the International Basal Ganglia Society (IBAGS; US) and the Spanish Society for Neurosciences (SENC; Spain). Since January 2017, he is serving as a Board Member of the IBAGS Council. In January 2020, he joined the board of the International Brain Research Organization Pan-European Committee (IBRO-PERC), as well as the Committee for Higher Education and Training from the Federation of European Neuroscience Societies (FENS-CHET). He has published 125 papers in international scientific journals. h index is 40 based on the ISI Web of Science (Sept 2021), contributed to ten chapters to scientific books, and co-edited three books. Currently available funding includes research grants from European agencies (H2020; JPND; ERC Advanced, CoEN-Pathfinder and Eranet-Neuron), from the Spanish Ministry of Science as well as from charities (Fundació La Marató TV3 and the Michael J. Fox Foundation for Parkinson’s Research). He has been recognized as “Group of Excellence” in the field of Neurodegenerative Diseases by the Spanish Ministry of Health since December 2006, therefore joining the so-called “Network Center for Biomedical Research in Neurodegenerative Disorders” as a founding member. In September 2019, he co-founded Handl Therapeutics B.V., a gene therapy company pushing forward the development of novel disease-modifying therapies for the treatment of Parkinson’s disease.